The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC).
 
Stephane Champiat
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche; SERVIER; Takeda
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; BeiGene; BioNTech SE; Celanese; Domain Therapeutics; Ellipses Pharma; Genmab; Immunicom; Mariana Oncology; Nanobiotix; NextCure; Oncovita; Pierre Fabre; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8
Research Funding - Abbvie; Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen; Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); BB Biotech Ventures (Inst); BBB Technologies (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAlliance Pharma (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics; Boston Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); CellCentric (Inst); Centessa Pharmaceuticals; Cephalon (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); CureVac (Inst); Cytovation; Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Eisai/H3 Biomedicine; Exelixis (Inst); Faron Pharmaceuticals (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); H3 Biomedicine (Inst); ImCheck therapeutics; Immunocore; Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Merus (Inst); Millennium (Inst); Molecular Partners; Molecular Partners (Inst); MSD; Nanobiotix (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Oncoethix (Inst); OncoMed (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); OSE Immunotherapeutics; Ose Pharma (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); Pierre Fabre; Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); Relay Therapeutics (Inst); Replimune; RigonTEC (Inst); Roche (Inst); Roche (Inst); Roche/Genentech; Sanofi; Sanofi (Inst); Sanofi/Aventis (Inst); Seagen; Seagen (Inst); SERVIER (Inst); Sierra Oncology (Inst); Sotio; Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tioma Therapeutics (Inst); Transgene; Transgene (Inst); Turning Point Therapeutics (Inst); Veracyte (Inst); Wyeth (Inst); Xencor (Inst); Y's Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio
Other Relationship - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NH TherAguix (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
 
Patrick Grierson
Employment - Walgreens (I)
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Jason Hsieh
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Guardant Health; Incyte; Lilly Japan; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Yu-Yun Shao
Honoraria - AstraZeneca/MedImmune; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche
Research Funding - AstraZeneca/MedImmune; Roche
Travel, Accommodations, Expenses - Roche
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; Roche/Genentech; SERVIER
Research Funding - AstraZeneca; Bayer; Boryung Pharmaceuticals; CKD pharm; Eisai; Lunit; SERVIER
 
Cristina Bergamaschi
Employment - AstraZeneca; Cartesian Therapeutics (I)
Stock and Other Ownership Interests - AstraZeneca; Cartesian Therapeutics (I)
Research Funding - AstraZeneca; Cartersian Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Cristina Bergamaschi is a listed inventor on US Government-owned patents related to heterodimeric IL-15. Cristina Cristina Bergamaschi is a listed inventor on an Astrazeneca patents related to AZD9793
 
Sarah Blanchette
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - Ipsen (Inst)
 
Lyndon Kirby
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune; GlaxoSmithKline
 
Anna Krotkova
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Elie Pommier
Employment - AstraZeneca/MedImmune
 
Maria Trissal
Employment - AstraZeneca; Takeda
Stock and Other Ownership Interests - Takeda
Travel, Accommodations, Expenses - AstraZeneca; Takeda
 
Frederick Goldberg
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Bharat Burman
Employment - Janssen (I)
Stock and Other Ownership Interests - Janssen (I)
Honoraria - Medscape
 
Stephen Chan
Honoraria - AstraZeneca; Eisai; Elevar Therapeutics; Ipsen; MSD (Inst); Roche
Consulting or Advisory Role - AstraZeneca; Eisai; Elevar Therapeutics; Exelixis; MSD Oncology; Roche
Research Funding - Eisai; MSD
Travel, Accommodations, Expenses - Ipsen; Roche